M. Soulié

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 740 citations

Medicine, Oncology, Urology +16

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly et al. · European Urology · 2015 · 462 citations

Medicine, Oncology, Urology +17

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial

Paul Sargos, Sylvie Chabaud, I. Latorzeff et al. · The Lancet Oncology · 2020 · 322 citations · Full text

Medicine, Oncology, Urology +17

Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery

Karim Bensalah, Allan J. Pantuck, Rodolphe Thuret et al. · European Urology · 2009 · 271 citations

Medicine, Oncology, Surgery +16

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

Christian Pfister, Gwénaëlle Gravis, Aude Fléchon et al. · European Urology · 2020 · 247 citations · Full text

Medicine, Oncology, Urology +14